{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:06:23Z","timestamp":1790892383610,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy is the standard treatment for neovascular age-related macular degeneration and other retinal vascular diseases. Despite proven efficacy in clinical trials, real-world data suggest suboptimal persistence and adherence. This study aimed to assess therapy continuity in routine practice using pharmacy-based dispensing data in Germany, focusing on treatment with prefilled syringes (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This retrospective cohort study used anonymised nationwide pharmacy sales data from Germany to evaluate patients who initiated anti-VEGF therapy with PFS between 2020 and 2023. Patient trajectories were followed from treatment initiation for up to 12 months. 46\u2009546 therapy beginners with 297\u2009454 anti-VEGF PFS purchases were included. Discontinuation of treatment was defined by not purchasing a relevant medication for &gt;6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean time on therapy for all patients was 8.1\u00b18.2 months (median=5.5) with 6.9\u00b16.1 purchases (median=5). 20.5% of patients initiating anti-VEGF treatment stopped therapy before completing the loading phase (first three injections), and more than half of all patients discontinued treatment after 6 months. 49.4% of the patients who completed the loading phase (n all=34\u2009895) adhered to the recommended monthly regimen. Non-adherence significantly decreased the number of injections later on (average of 7.5 vs 8.7 injections). Further, patients who stayed longer on therapy bought more PFSs within the first 6 and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world adherence and persistence to intravitreal anti-VEGF therapy in Germany are suboptimal, even with the use of PFS formulation. The high rate of early treatment discontinuation, especially during the loading phase, underscores the need for improved patient support, education and flexible treatment approaches to sustain long-term outcomes. A \u2018breaking point\u2019 or sensitive phase already seems to exist right at the beginning of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002334","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T01:05:35Z","timestamp":1762131935000},"page":"e002334","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Tracking real-world persistence and adherence to anti-VEGF intravitreal therapy with prefilled syringes: a German prescription sales analysis"],"prefix":"10.1136","volume":"10","author":[{"given":"Patrizia","family":"Brunner","sequence":"first","affiliation":[{"name":"Temedica GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Havanur","sequence":"additional","affiliation":[{"name":"Temedica GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffeni","family":"Papukchieva","sequence":"additional","affiliation":[{"name":"Temedica GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-9925","authenticated-orcid":false,"given":"Benjamin","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Temedica GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Clinic Leipzig, Leipzig, Germany"},{"name":"Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"key":"2026010721212020000_10.1.e002334.1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/s41433-022-02153-9","article-title":"15 years of anti-VEGF treatment for nAMD: success or failure or something in between?","volume":"36","author":"Chakravarthy","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026010721212020000_10.1.e002334.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ophtha.2024.12.018","article-title":"Age-Related Macular Degeneration Preferred Practice Pattern\u00ae","volume":"132","author":"Vemulakonda","year":"2025","journal-title":"Ophthalmology"},{"key":"2026010721212020000_10.1.e002334.3","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002670"},{"key":"2026010721212020000_10.1.e002334.4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.5","unstructured":"Gunnemann ML , Ziegler M , Book M , et al . Ist die exsudative neovaskul\u00e4re AMD eine chronische Erkrankung? Analyse von Langzeitverl\u00e4ufen unter einer Anti-VEGF-Therapie. Klin Monatsbl\u00e4tter F\u00fcr Augenheilkd 2024;2239\u20136394."},{"key":"2026010721212020000_10.1.e002334.6","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-021-00350-5"},{"key":"2026010721212020000_10.1.e002334.7","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721212020000_10.1.e002334.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"2026010721212020000_10.1.e002334.9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"The Lancet"},{"key":"2026010721212020000_10.1.e002334.10","doi-asserted-by":"publisher","DOI":"10.1159\/000502747"},{"key":"2026010721212020000_10.1.e002334.11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00347-020-01273-5","article-title":"Adh\u00e4renz bei der Anti-VEGF-Therapie \u2013 \u00dcberlegungen und praktische Empfehlungen","volume":"118","author":"Lommatzsch","year":"2021","journal-title":"Ophthalmologe"},{"key":"2026010721212020000_10.1.e002334.12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/IAE.0000000000001681","article-title":"TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study","volume":"38","author":"Ehlken","year":"2018","journal-title":"Retina"},{"key":"2026010721212020000_10.1.e002334.13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-024-06690-9","article-title":"Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis","volume":"263","author":"Krieger","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00347-018-0746-5","article-title":"Real-Life-Daten-Analyse der Therapiequalit\u00e4t bei Patienten mit exsudativer altersabh\u00e4ngiger Makuladegeneration (AMD) und ven\u00f6sen Gef\u00e4\u00dfverschl\u00fcssen an einer deutschen Universit\u00e4tsaugenklinik","volume":"116","author":"Treder","year":"2019","journal-title":"Ophthalmologe"},{"key":"2026010721212020000_10.1.e002334.15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308668"},{"key":"2026010721212020000_10.1.e002334.16","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.4103\/ijo.IJO_3066_21","article-title":"Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"70","author":"Dhingra","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.17","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41433-023-02474-3","article-title":"Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration","volume":"37","author":"Jones","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721212020000_10.1.e002334.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06362-w","article-title":"A model to quantify the influence of treatment patterns and optimize outcomes in nAMD","volume":"12","author":"Ziemssen","year":"2022","journal-title":"Sci Rep"},{"key":"2026010721212020000_10.1.e002334.19","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2016.1274040"},{"key":"2026010721212020000_10.1.e002334.20","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1007\/s00417-021-05324-8","article-title":"Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy","volume":"259","author":"Kellner","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.21","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s00417-017-3739-1","article-title":"Treatment of age-related neovascular macular degeneration: the patient\u2019s perspective","volume":"255","author":"M\u00fcller","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","article-title":"Systematic review: non-adherence and non-persistence in intravitreal treatment","volume":"258","author":"Ehlken","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40123-024-01061-3","article-title":"Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration","volume":"14","author":"Loewenstein","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"2026010721212020000_10.1.e002334.24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12237435","article-title":"The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data","volume":"12","author":"Wolfram","year":"2023","journal-title":"J Clin Med"},{"key":"2026010721212020000_10.1.e002334.25","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1038\/s41433-023-02439-6","article-title":"Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis","volume":"37","author":"Nichani","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721212020000_10.1.e002334.26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"2026010721212020000_10.1.e002334.27","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s00417-021-05302-0","article-title":"Intravitreal air bubbles following intravitreal injections: a comprehensive analysis","volume":"259","author":"Krauthammer","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/OPTH.S393519","article-title":"Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022","volume":"17","author":"Schmidt-Ott","year":"2023","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"2026010721212020000_10.1.e002334.29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000518236","article-title":"The Effect of Syringe-Filling Technique on the Risk for Endophthalmitis after Intravitreal Injection of Anti-VEGF Agents","volume":"245","author":"Finkelstein","year":"2022","journal-title":"Ophthalmologica"},{"key":"2026010721212020000_10.1.e002334.30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/09273948.2020.1820530","article-title":"Does Pharmaceutical Compounding of Vascular Endothelial Growth Factor Inhibitors for Intravitreal Use Alter the Risk of Post-injection Endophthalmitis?","volume":"30","author":"Blom","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"2026010721212020000_10.1.e002334.31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","article-title":"The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab","volume":"199","author":"Storey","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2026010721212020000_10.1.e002334.32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00347-024-01986-x","article-title":"H\u00e4ufigkeit und Wirkstoffverteilung intravitrealer Injektionen in deutschen Zentren 2015 bis 2021 \u2013 eine oregis-Studie","volume":"121","author":"Zimmermann","year":"2024","journal-title":"Ophthalmologie"},{"key":"2026010721212020000_10.1.e002334.33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-022-00596-7","article-title":"The Treatment Patterns with Brolucizumab in Germany (REALIZE) Study: A Retrospective Cohort Study Based on Longitudinal Prescription Data","volume":"12","author":"Liegl","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"2026010721212020000_10.1.e002334.34","doi-asserted-by":"publisher","DOI":"10.5301\/EJO.2011.7430"},{"key":"2026010721212020000_10.1.e002334.35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"2026010721212020000_10.1.e002334.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"2026010721212020000_10.1.e002334.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis","volume":"12","author":"Shahzad","year":"2023","journal-title":"Syst Rev"},{"key":"2026010721212020000_10.1.e002334.38","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1080\/03007995.2016.1221803","article-title":"Real world evidence of use of anti-VEGF therapy in Denmark","volume":"32","author":"Vorum","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2026010721212020000_10.1.e002334.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS ONE"},{"key":"2026010721212020000_10.1.e002334.40","first-page":"3335","article-title":"Real-world treatment patterns in injection cost and frequency for ranibizumab versus aflibercept in patients with wet age-related macular degeneration: a 2-year US claims analysis","volume":"57","author":"Kiss","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721212020000_10.1.e002334.41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00347-018-0747-4","article-title":"Pro-re-nata-anti-VEGF-Behandlungsergebnisse bei neovaskul\u00e4rer altersabh\u00e4ngiger Makuladegeneration in der klinischen Routineversorgung: Vergleich von Einzel- mit 3er-Injektionen","volume":"116","author":"Wintergerst","year":"2019","journal-title":"Ophthalmologe"},{"key":"2026010721212020000_10.1.e002334.42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/RMHP.S80536","article-title":"Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data","volume":"8","author":"Reich","year":"2015","journal-title":"Risk Manag Healthc Policy"},{"key":"2026010721212020000_10.1.e002334.43","first-page":"1260","article-title":"Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis","volume":"27","author":"Almony","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2026010721212020000_10.1.e002334.44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/aos.15094","article-title":"What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register","volume":"100","author":"L\u00f6vestam Adrian","year":"2022","journal-title":"Acta Ophthalmol"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:22:20Z","timestamp":1767849740000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,2]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjophth-2025-002334"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002334","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}